Following a period of slow progress, the completion of genome sequencing and the
paradigm shift relative to the cell of origin for high grade serous ovarian cancer (HGSOC) led …

Background When determining adjuvant treatment for endometrial cancer, the decision
typically relies on factors such as cancer stage, histologic grade, subtype, and a few …

Highlights•46 participants from 15 countries across Europe, Asia and the USA contributed to
the ESGO–ESMO–ESP consensus conference.•Recommendations cover diagnosis and …

Chromosomal instability (CIN) is a hallmark of cancer, caused by persistent errors in
chromosome segregation during mitosis. Aggressive cancers like high-grade serous ovarian …

Although cancer-associated fibroblast (CAF) heterogeneity is well-established, the impact of
chemotherapy on CAF populations remains poorly understood. Here we address this …

Molecular abnormalities that shape human neoplasms dissociate their phenotypic
landscape from that of the healthy counterpart. Through the lens of a microscope, tumour …

Background Ovarian carcinosarcoma (OCS) is an exceptionally aggressive and
understudied ovarian cancer type harbouring distinct carcinomatous and sarcomatous …

High-grade serous ovarian carcinoma (HGSOC) is genetically unstable and characterised
by the presence of subclones with distinct genotypes. Intratumoural heterogeneity is linked …

DNA methyltransferase inhibitor (DNMTi) efficacy in solid tumors is limited. Colon cancer
cells exposed to DNMTi accumulate lysine-27 trimethylation on histone H3 (H3K27me3). We …

The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of
the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we …